MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Search

Adverum Biotechnologies Inc

Ouvert

SecteurSoins de santé

4.3

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+11.93% upside

Sentiment de l'Actualité

By Acuity

50%

50%

177 / 360 Classement par Healthcare

Adverum Biotechnologies Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 oct. 2025, 13:04 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Agrees to Acquire Adverum Biotechnologies

9 déc. 2025, 13:32 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: Parties Expect to Consummate the Acquisition on Dec 9 >LLY

9 déc. 2025, 13:32 UTC

Acquisitions, Fusions, Rachats

Lilly and Purchaser Accepted for Payment, and Will Promptly Pay, for All Shrs

9 déc. 2025, 13:29 UTC

Acquisitions, Fusions, Rachats

Lilly and Adverum Announce Expiration and Completion of Adverum Tender Offer and Acquisition

24 oct. 2025, 12:34 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY

24 oct. 2025, 12:34 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY

24 oct. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

24 oct. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Lilly To Acquire Adverum Biotechnologies >LLY ADVM

Comparaison

Variation de prix

Adverum Biotechnologies Inc prévision

Objectif de Prix

By TipRanks

11.93% hausse

Prévisions sur 12 Mois

Moyen 4.88 USD  11.93%

Haut 5.5 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

2

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

177 / 360Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

$

help-icon Live chat